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productivity, and generational accounting, which accounts for a range of other gov-
ernment fiscal transfers to citizens. The possible produced value for a life-time term 
was assumed as calculating the total NPV depending on the life expectancy. CPD 
was assumed as the difference between NPV on the year of life expectancy and each 
decades as life years 50, 40, 30, 20, 10 and new born. The economic values for the 
model were derived from World Bank, OECD, UNESCO or WHO. Results: Possible 
produced value for a life-time term for Turkey was calculated as US$ 483.298. Cost 
of pre-mature death per person was calculated as US$ - 102.064, US$ - 271.716, US$ 
-441.679, US$ -583.726, US$ - 518.753,14 and US$ - 483.986 for the life years new born, 
10, 20, 30, 40 and 50 respectively. ConClusions: However the study was based 
on a hypothetical model that calculated the NPV with the taxes and spending in a 
life-time term, cost of premature death was calculated as the highest in early ages 
and was decreasing up to the retirement age. The results may be reference for the 
decision makers. Health policy makers may improve the access to the treatments 
in the early life years for the possible increased cost of premature deaths in Turkey.
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objeCtives: Drug-drug interaction is a common error in poly-medication and con-
tributes a major part in adverse drug reactions. The aim of the present study was to 
evaluate the percentage of potential drug-drug interactions in the prescription in the 
region of South Punjab Pakistan prescribed by the medical practitioner Methods: A 
total of 100 prescriptions were included in this study. Institution based retrospective 
study was performed in Nishter Hospital Multan, Pakistan, the 3rd oldest medical 
institution of Pakistan, which has a capacity of 1800 beds and having a best facil-
ity to hold a large number of emergencies at a time. Prescriptions were collected 
to see the Drug - Drug interactions and compared with the standard reference of 
important DDI’s. The potential drug-drug interactions were categorized according 
to their severity, effect and mechanism. Results: The study showed that among 
100 prescriptions (543 medicines), 41% of prescriptions have potential DDI’s. Mostly 
prescribed drugs were the antibiotics (38%), and the drugs belonging to class analge-
sic were found to contribute mostly in drug-drug interactions (26.50%). The survey 
showed the total of 71 interactions and their severity level accounting as major 
(20.10%), moderate (63.4%) and minor (15.90). The mechanism by which the drugs 
interact with one another showed that there were pharmacokinetic (60.5%), pharma-
codynamic (38.6%) and few of them interact by the mechanism which was not speci-
fied in the available literature (0.9%). ConClusions: Drug-drug interactions occur 
in poly-medication and need to be evaluated and monitored for the positive impact 
on the medication use system and improvement of quality of patient care. A clini-
cal pharmacist with its accurate knowledge of drug, their effect on human organs 
and their interaction with other can monitor and manage these drug interactions.
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objeCtives: The Human Capital Theory emphasizes investments to the health care 
sector as an important element in achieving and sustaining economic development. 
Investments to health care sector improves macro and micro economic outcomes 
for the whole society. The aim of this study is to calculate the possible produced 
value for a life-time term (VLT) and cost of pre-mature deaths (CPD) from the pro-
ductivity for Argentina, Brazil and Mexico. Methods: Net present value (NPV) of 
the taxes and spending for each year were calculated. For calculating NPV in the 
government perspectives, two modelling approaches were combined, human capital 
modelling based on lives saved and lost productivity, and generational accounting, 
which accounts for a range of other government fiscal transfers to citizens. The 
possible produced value for a life-time term for each country were assumed as cal-
culating the total NPV for each country depending on the countries life expectancy. 
CPD for each countries were assumed as the difference between NPV on the year 
of life expectancy and each decades as life years 60, 50, 40, 30, 20, 10. The economic 
values for the model of each country derived from World Bank, OECD, UNESCO or 
WHO. Discount rate and inflation for wages were taken as 3% per year for all coun-
tries. Results: Possible produced VLT for each country were calculated as US $ 
716.945, US$ 663.129 and US$ 653.598 for Argentina, Brazil and Mexico, respectively. 
CPD per person for Argentina were calculated as US$ -666.234, US$ -657.861, US$ 
-512.554, US$ -338.675, US$ - 164.722 and US$ -24.615 for the life years 10, 20, 30, 40, 
50 and 60 respectively. The trend was same for Brazil and Mexico. ConClusions: 
However the study was based on a hypothetical model that calculated the NPV with 
the taxes and spending in a life-time term, the results of each country were parallel.
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Pharmaceutical expenditure as has been increasingly grown during the last decades 
so that policy makers have paid more and more attention to develop strategies 
to deal with this challenging issue. Pharmacists play an important role in health 
continuum to implement such strategies through dispensing and delivering generic 
medicines to consumers. So, the main objective of this study was to explore the per-
ception of Iranian pharmacists regarding generic substitution, and also to explore 
how Iranian pharmacists think about patients’ role, physicians’ role and government 
role in generic substitution. A cross sectional descriptive study involving the entire 
population of Tehran community pharmacies (n = 2000) was performed using a 
self-administrated anonymous questionnaire. A total of 1205 questionnaires were 
returned indicating a response rate of 60%. Regarding to the first section, 62% of 
participants agreed that pharmacists should be given right to generic substitu-
tion, and 45% viewed that the generic medicine are bioequivalent with brand ones. 
Majority of the respondents (73.6%) stated that, they do substitution once generic 
medicine is available. However, they think that patients, physicians and government 
have important role in generic substitution. More than half (75.5%) of pharmacists 
believed physicians’ prescription behavior highly influenced by the marketing 
and promotion activities of foreign companies. 93% of respondents pointed to full 
coverage of generic medicines by providers as a strategy to generic substitution. 
Summary, evidences indicated that Iranian pharmacists have good insights regard-
ing implementation and promotion of generic substitution strategy.
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objeCtives: This paper was aimed to introduce how we developed a “high-alert/
high risk medications reminder system” operated in the computer system to 
improve medication safety in our hospital. Methods: This reminder system was 
designed in a 2,400-bed health institute with 2,000 nurses, consisting of 12 nursing 
divisions and 75 units. The new module was added to the current BCMA system with 
VB. net. The functions of this computer system include seven steps. Results: A 
satisfaction and cognition survey on the application of the new, computerized “high-
alert/ high risk medications reminder system” was done to MICU nurses (N= 36). The 
survey response rate was 100%. The results showed high rate of positive support 
on the new system due to easy to access and easy to learn. The satisfactory rate 
comparing the old paper form system and the new computer system was 62.8% vs. 
96.1%. More importantly, the “high-alert/high risk medications reminder system” 
appeared to reduce the administration error rate from 5 cases in 2011 to 0 cases 
in 2012. ConClusions: Our early experience showed that an efficient and user-
friendly “High-Alert/High Risk Medications Reminder System” could be helpful for 
medical staffs to improve medication safety although a longer follow-up time to 
evaluate the efficacy of the computerized system is still needed before a final con-
clusion can be established. In addition, we are also keen to investigate whether this 
system could reduce the waste of time, expenditure, and manpower in a medical 
center in our future study.
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objeCtives: At the global level the large deployment of telemedicine raises needs 
for cost-effectiveness evaluations. The objective of this literature review is to explore 
to what extend telemedicine innovations that were implemented in many countries 
were cost-effective. Specifically, we explore whether the model used to evaluate the 
cost-effectiveness can be adapted to the evaluation of telemedicine technologies. 
So, what answers can a review of the international literature relating to the med-
ico-economic evaluation of telemedicine provide? Methods: Following analytical 
reading of 286 articles published between 2000 and 2013, 74 studies that imple-
mented economic evaluation of telemedicine are analysed. Three axis of analysis 
are considered: the act concerned by the telemedicine intervention, the medical 
speciality, the economic evaluation method implemented. Results: The descrip-
tive analysis showed significant heterogeneity in studies characteristics: economic 
analysis method, telemedicine applications, medical specialities, and organisational 
practices. The qualitative analysis underlines that most studies face methodological 
issues and provide reduced evidence of the economic impact of the telemedicine 
interventions. The telemedicine technologies are too individualised (by the context 
and the organisation) to be evaluated using the standards of cost-effectiveness 
analysis. ConClusions: This literature review did not allow proposing a classifica-
tion for telemedicine practices identified as efficient, depending on the strategies 
compared, field of application or speciality, types of telemedicine or an organisation 
of care model. Despite all this, one focus can be the management of chronic diseases 
that remains a central topic at the international level. The increase in the number 
of medical specialities or fields of application concerned with telemedicine and 
the increased volume of activity necessitate the dissemination of methodological 
recommendations to promote the coherent development of economic evaluations. 
Our literature review shows that there is need to develop innovative methods to 
assess the cost-effectiveness of telemedicine technologies.
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objeCtives: An indicator is a clue that helps a health care organization to iden-
tify adverse drug events and assess the overall harm that occurs from medical 
care within that organization. The main aim of the study was to investigate use 
of an indicator list for identification of adverse events in the health care setting 
studied. Methods: The study was a prospective observational study in a tertiary 
care teaching hospital. The study mainly involves the review of medical records of 
patients in general medicine department who were admitted due to drug related 
problems with the help of trigger tool. When the presence of indicator is identified, 
those cases were thoroughly scrutinized to identify adverse drug events and confirm 
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such events in the light of available evidence and discussion with the treating physi-
cians. Results: A total of 275 patients were included in the study for case review 
as per the study criteria. Out of 275 patients, 150 patients had at least one indicator 
(55%) and detection of adverse events was about 19.2%. Ratio of actual adverse event 
detected to the presence of indicators was calculated as true positives. The average 
true positive value of indictors was 33%. Average number of indicators present per 
patient was determined to be 3.82. The harm categorization was carried out for 
the observed adverse events as per National Coordinating Council for Medication 
Error Reporting and Prevention (NCC MERP). ConClusions: The present study 
showed that indicator tool could be used to review the cases prospectively and 
identify adverse events. The identified indicators showed the pattern and frequency 
of adverse events. Findings of our study supported the idea of making the indicator 
tool as a practical aid for identification of adverse events.
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The pharmaceutical care concept has been popular in the world during past dec-
ades, but it did not reach well to its maturity in some countries, so the investigation 
on barriers to the implementation of the pharmaceutical care in these countries 
would be great of interest. objeCtives: The aim of the study was to identify and 
prioritize barriers to the provision of pharmaceutical care in Iranian community 
pharmacies based on Tehran community pharmacists’ perceptions. Setting The pre-
sent study was conducted with participation of pharmacists working in community 
pharmacies settled in Tehran, the capital city of Iran. Methods: A cross-sectional 
descriptive study was performed using an anonymous questionnaire between 
August and November 2013. 505 community pharmacists expressed their percep-
tions on items by a 5-point Likert-type scale. Besides descriptive analysis, data was 
also analyzed through structural equation modeling. Main outcome measured was the 
importance perceived by community pharmacists in the case of 5 area including 
resources, attitude and vision, education and training, skills, regulatory and environ-
mental issues. Results: Five major dimensions included in the survey instrument 
were confirmed by confirmatory factor analysis. According to the model developed 
based on pharmacists’ opinions, lack of pharmacists’ skills and lack of appropriate 
regulation and environment are the two most important barriers of the provision of 
pharmaceutical care, and the least important is lack of resources. ConClusions: 
Findings of the present study showed that importance of various barriers vary from 
country to country based on the pharmacists’ perceptions, and corrective actions 
should be made accordingly.
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objeCtives: MediGuide technology is designed to monitor the position of diagnos-
tic and therapeutic catheters equipped with a sensor MediGuide and navigation in 
vascular or cardiac intervention in the environment of electro-physiological labora-
tory. MediGuide compared to conventional technology, offers the 3D display on the 
live fluoroscopy or recorded background, radiation burden reduction, fluoroscopy 
time and total time performance. The aim of this thesis is to analyze the clini-
cal and cost effectiveness of new technologies MediGuide in the Czech Republic. 
Results of the analysis are being compared to the studies of the German Cardiac 
where technology is positively evaluated. Methods: The evaluation method is 
cost-effectiveness analysis, which compares technology system MediGuide to a 
comparator angiography Siemens Artis Zee. Value of the effect was determined by 
TOPSIS in which they were entered weight values obtained by Saaty method of pair 
comparison by group of experts. The sum of direct costs includes costs associated 
with the operation of both technologies. Calculated values of costs and effects were 
achieved in incremental ICER assessment ratio, fixing the amount of costs per unit of 
effect. Results: More appreciated criteria in Saaty method were: safety and effec-
tiveness of the technology. The fundamental values of the following criteria in this 
method were used: radiation burden, which in the Czech Republic reached values 
using conventional technology 575±511μ Gy. m2 and in Germany 14,453±7,403μ Gy. 
m2, fluoroscopy time values for Czech Republic 7.5±4.5min; Germany 34±9min and 
total time performance of Czech Republic 148±91 min; Germany 157±51min. The 
cost of power at the treatment of 100 patients was in the first year to CZK 181,711; 
MediGuide under the same conditions CZK 276,765. ConClusions: Manufacturer 
of MediGuide values technology as an effective, safe and value-added reduce the 
radiation burden of the patient, fluoroscopy time and shorten the overall time per-
formance.
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objeCtives: Gaining reimbursement is a complex process that involves gener-
ating the right evidence and communicating it successfully to stakeholders. To 
ensure alignment of the value story across countries and help affiliates in their 
local submissions, headquarters (HQ) develop the global value dossier (GVD). We 
have investigated whether the current GVD meets HQ and local affiliates (LAF) 
expectations. Methods: Pharma HEOR and market access professionals from HQ 
and LAF were invited to participate in telephone interviews to assess their views 
on current use and utility of the GVD. Results were analyzed to identify differences 
and alignments between HQ and LAF. Results: 43 [16HQ/27LAF] professionals were 
invited; 22 [8HQ/14LAF] tentatively agreed to participate and 15 [7HQ/8LAF] were 
finally interviewed. Compared to LAF, HQ perceive the GVD more useful (HQ: 100%; 
LAF:63%) and capable of positively influencing the final outcome of submissions 
(HQ:86%; LAF:50%). Compared to HQ, LAF consider the GVD is delivered too late 
(LAF:88%; HQ:13%) and that LAF should be involved in GVD development (LAF:100%; 
HQ:71% but only for review). HQ consider that LAF involvement should be restricted 
to the GVD review while LAF think they should participate in building the value 
story (63%) or the economic model (37%). LAF prefer a modular GVD with each 
component delivered separately (LAF: 88%; HQ: 66%), request national data to be 
included (LAF:63%; HQ:14%), and cannot see the utility of new technologies for the 
GVD (LAF:75%; HQ:33%). HQ and LAF expect the GVD to be updated continuously 
(HQ:6%; LAF:75%) and be supplemented with phase IIIb data for potential resubmis-
sions (HQ:100%; LAF:88%). ConClusions: HQ and LAF expectations differ particu-
larly on how soon the GVD should be made available, the involvement of affiliates 
during its development and the applicability of the GVD contents to local submis-
sions. How to address these discrepancies to ensure alignment will be discussed.
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objeCtives: In German hospitals there is a need for optimized crisis- and risk 
management. About one third of all hospital-acquired patient damages are due to 
medication errors. The aim of our interdisciplinary project “Risk Management in 
Hospitals” is to analyze the behavior of the various key players in the fields of medi-
cal care, human resources, supply and IT-systems in the context of various simu-
lated risk scenarios as well as to develop adequate risk management tools. In this 
abstract, the first results on medication errors are presented. Methods: Through 
a network of experts, systematic literature searches and expert workshops, the five 
most relevant crises from different disciplines (medical, HR, supply and IT) were 
identified and specified. In a standardized survey among German hospital managers 
further data were collected on these crises, their management and influencing fac-
tors. The results on medication errors presented here are based on the survey data 
using a linear regression model. Results: The analysis was based on fully com-
pleted questionnaires by 97 German hospitals. 70% of the hospitals reported that 
crises due to medical errors occurred in the last 5 years, which could not be handled 
with established risk management tools. Although the crisis-appearance was lower 
in private hospitals (28%) compared to publicly funded (31%) and nonprofit (41%) 
hospitals, this difference was not significant. We recognized that a high frequency 
in the occurrence of medical errors was significantly associated with a lower evalu-
ation of risk management issues (e.g. the presence of a staff member responsible 
for risk management, scenario analysis and crises trainings). ConClusions: Our 
study confirms that German hospitals have to expand their targeted risk man-
agement activities in order to prevent the occurrence of hospital crises especially 
due to medical and medication errors. All survey results will be incorporated in a 
decision-making and benchmarking-tool for hospital managers to improve crisis 
management in German hospitals.
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objeCtives: A Budget Impact Analysis (BIA) analyses the financial consequence 
associated with the uptake of a new treatment option in the market; which can 
impact planning and forecasting and influence changes to pharmaceutical and 
health care budgets. Therefore, BIA forms a key consideration of the Dutch Health 
Care Insurance Board (ZiNL) when making a reimbursement decision regarding a 
new treatment intervention. The current analysis investigates consistent trends 
observed between the predicted budget versus the actual budget spent on reim-
bursed drugs in the Netherlands. Methods: Forecasted data specific to new drugs 
reimbursed under list 1B between 2009 and 2013 were extracted from drug reim-
bursement reports available from the ZiNL website. Actual data of the selected drugs 
were extracted from the Drug and medical devices Information Project database 
(GIP database). Per year and cumulative (between 1 and 5 years) data on total drug 
cost, total number of users and total cost per patient were compared between the 
forecasted values and the actual values. Results: In total 20 drugs were included in 
the analysis, of which 12 presented data for 3 years or more. Compared to the actual 
data, the expected total drug cost was overestimated for 14 drugs, total number of 
users was overestimated for 12 drugs and for 10 drugs the total cost per patient was 
overestimated. Total number of users was most accurately estimated, presenting a 
pooled cumulative overestimation of 5 times the actual number of users. Total drug 
cost was least accurately estimated (pooled cumulative overestimation of 13 times 
the actual total cost), since the total drug cost includes the uncertainty reflected 
in both the total number of users and total cost per patient. ConClusions: The 
expected budget of 1B drugs in reimbursement submission reports generally over-
estimated the actual budget presented in the GIP database between 2009 and 2013.
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objeCtives: Budget impact analyses are an essential component in the economic 
evaluation of new drugs. These analyses allow the health care payer to assess the 
likely impact of the drug on the payer’s budget, and to plan for short- and long- term 
